JP Morgan Chase
RLMD icon

JP Morgan Chase’s Relmada Therapeutics RLMD Stock Holding History

JP Morgan Chase’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-89,800
Closed -$46.7K – 7661
2024
Q4 		$46.7K Hold
89,800
– – ﹤0.01% 6041
2024
Q3 		$291K Sell
89,800
-5,300
-6% -$17.2K ﹤0.01% 5223
2024
Q2 		$285K Buy
95,100
+40,000
+73% +$145K ﹤0.01% 4962
2024
Q1 		$256K Buy
+55,100
New +$266K ﹤0.01% 5213

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase's RLMD Position: Q2 2026 in Review

JP Morgan Chase opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 39,203 shares worth $274K. The stake represents ﹤0.01% of the portfolio and ranks #5445 among its holdings. This is a return to the name: JP Morgan Chase previously reported a position in RLMD as recently as Q2 2025.

JP Morgan Chase first reported a position in RLMD in Q2 2020 and has held it in 22 quarters since. The position peaked at $1.06M in Q2 2024. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • JP Morgan Chase held 39,203 shares of Relmada Therapeutics worth $274K as of Q2 2026.
  • Relmada Therapeutics was a new JP Morgan Chase position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #5445 holding.
  • JP Morgan Chase first reported a position in Relmada Therapeutics in Q2 2020 and has held it in 22 quarters since.
  • JP Morgan Chase's Relmada Therapeutics position peaked at $1.06M in Q2 2024.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.